White Paper

Human ADME & Studies With Radiolabeled Compounds

Source: PRA Health Sciences

By Ad Roffel and Henk Poelman, PRA Health Sciences

During clinical drug development there can be several situations where the use of radiolabeled medication or other radiolabeled compounds is required or favorable to accomplish the study objectives. This whitepaper is mainly focusing on human ADME studies and “microdose” studies to assess absolute bioavailability (BA). The major part of the information in this overview is also relevant for other clinical studies with a radiolabeled compound.